 | Up a level |
Chamuleau, Martine E D; Stenner, Frank; Chitu, Dana A; Novak, Urban; Minnema, Monique C; Geerts, Paul; Stevens, Wendy B C; Zenz, Thorsten; van Imhoff, Gustaaf W; Wu, Ka Lung; Demandt, Astrid M P; Kersten, Marie Jose; Terpstra, Wim E; Tick, Lidwine W; Deeren, Dries; Van Den Neste, Eric; Gregor, Michael; Veelken, Hendrik; Böhmer, Lara H; Caspar, Clemens B; ... (2023). R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial. The Lancet. Haematology, 10(12), e966-e975. Elsevier 10.1016/S2352-3026(23)00279-X
Maan, Raoel; Zaim, Remziye; van der Meer, Adriaan J; Feld, Jordan J; Wedemeyer, Heiner; Dufour, Jean-François; Lammert, Frank; Manns, Michael P; Zeuzem, Stefan; Hansen, Bettina E; Janssen, Harry LA; Veldt, Bart J; de Knegt, Robert J; Uyl-de Groot, Carin A (2016). Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. Journal of gastroenterology and hepatology, 31(11), pp. 1851-1859. Wiley-Blackwell Publishing Asia 10.1111/jgh.13373
